Abbott Laboratories (ABT) reports robust earnings growth and margin expansion, driven by medical devices, despite headwinds ...

The Motley Fool. DATE Thursday, July 17, 2025 at 9 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer — Robert ...

Q2 2025 Earnings Call Transcript July 17, 2025 Abbott Laboratories reports earnings inline with expectations. Reported EPS is ...

Q2 2025 Results Conference Call July 17, 2025 9:00 AM ETCompany ParticipantsMichael Comilla - Vice President of ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Barclays analyst Matt Miksic maintained an Overweight rating and increased the price target from $158 to $159 on April 17, 2025. This analyst has an accuracy rate of 66%. Stifel analyst Rick Wise ...

Live Updates Live Coverage Updates appear automatically as they are published. Still no earnings at 7:05 a.m. ET 7:04 am by ...

"Halfway through the year, we delivered high single-digit organic sales growth, double-digit EPS growth, significantly ...

Abbott posted Q2 revenue of $11.14 billion and EPS of $1.26, raised 2025 earnings guidance, and saw strong growth in diabetes ...

Abbott Laboratories (NYSE:ABT) is one of the Best Dividend Stocks of 2025. In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers ...

In the first quarter of 2025, the company delivered strong earnings and outperformed a group of medical device peers, despite challenging conditions driven by tariffs.